ArticleOncoimmunology2021
Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis.
Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.Frontiers in immunology · 2024Pooled it
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.Journal of the American Society of Nephrology : JASN · 2026Article
- Immune checkpoint inhibitor-associated interstitial nephritis: let's move forward addressing the unknowns.Clinical kidney journal · 2026Review
- TNF-α blockade mitigates immune checkpoint-related nephritis in a humanized mouse model.JCI insight · 2026Article
- Short versus long corticosteroid therapy for immune checkpoint inhibitors-induced acute tubulointerstitial nephritis.Clinical kidney journal · 2026Article
- Immune checkpoint inhibitor-related acute kidney injury: A diagnostic and therapeutic challenge for nephrologists.World journal of nephrology · 2026Review
- Cytokine release syndrome in solid tumours: mechanism-based therapeutic strategies for prevention and management.Therapeutic advances in medical oncology · 2026Review
- Risk stratification for immune checkpoint inhibitor rechallenge after acute kidney injury: towards a precision medicine framework.Frontiers in immunology · 2026Review
- Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence.Kidney international reports · 2026Article
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
- Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease.World journal of nephrology · 2025Article
- Urgent considerations on renal immune-related adverse events in oncology practice.Frontiers in immunology · 2025Review
- Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2024Review
- Immune checkpoint inhibitors and acute kidney injury.Frontiers in immunology · 2024Review
- Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.International journal of molecular sciences · 2023Review
- Article
- Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.Immunological reviews · 2023Review
- Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.Journal for immunotherapy of cancer · 2023Article
- Apoptotic cell death in disease-Current understanding of the NCCD 2023.Cell death and differentiation · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Acute tubular interstitial nephritis (ATIN) is the most frequently reported pathology in patients with checkpoint inhibitor (CPI) induced acute kidney injury (AKI). Glucocorticoid (GC) therapy and discontinuation of CPI are the mainstay of treatment to prevent permanent renal dysfunction and dialysis. However, less than 50% of patients have complete kidney recovery and relapse of ATIN can occur. Infliximab is effective in treating other immune-related adverse events but its use for the treatment of CPI-ATIN is not well established. We report the first retrospective study examining the steroid-sparing potential of infliximab in achieving durable and complete renal recovery for patients with CPI-ATIN. Data were collected from medical records of patients diagnosed with CPI-AKI with a kidney biopsy or clinical diagnosis of ATIN that was managed with GC and infliximab. Infliximab-containing regimens were used to treat 10 patients with CPI-ATIN. Four patients relapsing after GC therapy achieved durable and complete renal recovery, four patients experienced partial renal recovery, and two patients showed no improvement in kidney function. This is the first study evaluating clinical outcomes using an infliximab-containing regimen for treatment of relapsed CPI-ATIN in patients or patients failing to achieve complete response after primary therapy. Our data suggest that infliximab may be a treatment option for achieving durable and complete renal recovery in this patient population and represents a potential steroid-sparing strategy in challenging cases of CPI-ATIN. Rigorous clinical studies are warranted to evaluate the risk-benefit analysis for infliximab usage in CPI-ATIN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.